Close menu

April 27th, 2022 | 11:54 CEST

Where the sentiment is right: BioNTech, Defence Therapeutics, Amazon

  • Biotechnology
Photo credits:

If you want to sell air mattresses in November, you will not succeed even with huge discounts. It is a similar story when selecting stocks. In order to reap returns, investors need to assess the market and bet on the stocks that will be in demand in the near future. In the case of vaccine stocks, the air seemed to be out recently. But now, there are growing indications that more vaccine doses may be needed. We take a look at the sentiment of three stocks.

time to read: 4 minutes | Author: Nico Popp

Table of contents:

    BioNTech: What is still to come?

    On a one-year horizon, the BioNTech share has a return of only 1%. This is all the more remarkable because the share price has risen by more than 100% during this period. Recently, more and more people have been saying that the pandemic has run its course and that demand for vaccines would therefore decline. Although the new relaxed attitude is making itself felt in supermarkets and at other events in Germany these days, there are also new warning signals. A Pfizer-funded study shows that the current BioNTech vaccine's protective efficacy against hospitalizations is 85% within the first three months but drops to 55% after that. The findings could lead to more younger people reaching for the fourth vaccination.

    It was recently revealed that some vaccine doses were at risk of expiring this summer. Therefore, the new study situation is unlikely to generate additional sales for BioNTech. Looking ahead to the fall, however, demand could pick up again. An updated vaccine is expected then. Against the background of the then beginning cold season, the fourth prick would again be close at hand for many people. BioNTech's stock represents more than just a provider of Corona vaccines - mRNA technology is powerful and could also lead to breakthroughs in cancer. If so, BioNTech would finally have arrived in the biotech Olympus. Even if you ignore the price excesses of the past two years, the value remains in an upward trend. However, investors are not getting a bargain with the BioNTech share.

    Defence Therapeutics: Patented drug enhancer as a multi-tool

    Defence Therapeutics, on the other hand, is a different story. The biotech Company from Canada is also pursuing a platform approach and has several irons in the fire. The Company is working on antibody-drug conjugates (ADCs) and has presented impressive results. These ADCs are capable of amplifying active substances and delivering them directly into an affected cell. Defence Therapeutics' patented Accum™ technology is being used around vaccines against COVID-19 and HPV, as well as breast and skin cancer. Several Phase 1 studies are planned for this in the coming months. The conditions for a successful outcome appear favorable. "Such studies cost money. Given our encouraging results to date and the versatility of our technology, we are finding receptive ears in discussions with potential funders," said Dr. Moutih Rafei, Director and VP of Research and Development, Defence Therapeutics, in an interview.

    Even without agents associated with Accum™, the technology appears potent: "Accum™ is very toxic. We found that cancer cells die when we inject the drug directly into tumors. At the same time, Accum™ provides synergistic effects with other existing therapies. Specifically, this means that Accum™ is effective against cancer cells on the one hand but also supports other known active ingredients on the other. Possible application areas include breast cancer and previously incurable brain tumors, so-called glioblastomas. The only important thing is that Accum™ can be injected directly into the tumors. There are already experts who can use active substances in such a targeted manner. However, we are still a long way from a concrete application of Accum™ in this way," says Rafei. Initially, however, Defence Therapeutics intends to focus on patients with breast and skin cancer. Collaborations with clinics are already in place for this purpose. Most recently, the Company also obtained another patent that provides additional protection for the use of Accum™ around vaccines. This should also reduce the risk of competitors copying the approach and increase the likelihood that the Company will find cooperation partners around individual areas of application or license its technology. The stock has come back in a similar fashion to BioNTech but is still in solid charting waters. Due to the Company's relative unfamiliarity and the fact that it has not yet reached market maturity, the risk-reward profile is much more pronounced.

    Amazon: This success is timeless

    When it comes to buying stocks that are booming right now, the Amazon share cannot be missed. While some pandemic stocks, such as Peloton or even Netflix, have recently gone under the wheels, Amazon has held comparatively steady. The reason: the business model works even after the pandemic. More and more people were already shopping online in 2019, and the pandemic has only strengthened the trend. Part of the pandemic exaggeration has been relieved by Amazon, which is now hovering between USD 2,500 and USD 3,000. The lower end of this range could offer interesting opportunities. There are many reasons for the stock: in addition to the timeless business model, the weakness of competitor Netflix could also be an argument for Amazon.

    Whether biotech or retail, both sectors have a future, as long as entry into the respective shares is not too expensive. Timing always becomes a challenge when share prices are already pricing in a rosy future. That is most likely the case with BioNTech. As a market leader, Amazon is, of course, not cheap either. On the other hand, investors can seize opportunities in second-tier stocks that the market has not yet given an advance. One example of such a company is Defence Therapeutics.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Stefan Feulner on June 6th, 2023 | 07:15 CEST

    MediGene, BioNTech, BioNxt Solutions - New opportunities after the correction

    • Biotechnology
    • Pharma
    • Cancer

    Acquisitions by big pharma were increasingly expected in the biotechnology sector last year, but these largely failed to materialize. However, this trend could accelerate in the current year. On the one hand, pharmaceutical companies, such as the vaccine manufacturer Pfizer, have deep pockets and need new innovations for their product portfolio. On the other hand, second-tier stocks are attractive targets due to the strong correction.


    Commented by Juliane Zielonka on June 1st, 2023 | 09:30 CEST

    BioNxt Solutions, Bayer, Palantir - AI is dominating the market at breathtaking speed and ensuring high returns

    • Biotechnology
    • Pharma
    • AI

    Tech investors have suffered heavy losses over the past year. But tech in pharma and security in defence enables entirely new future scenarios whose precise developments are worth examining more closely. For example, gentler and more effective new ways that benefit patients are emerging in the drug delivery market. At the forefront is the Company BioNxt Solutions, which specializes in innovative transdermal patches whose active ingredients literally go under the skin. In Germany, the biotech company cooperates with a German pharmaceutical partner. New times are now dawning for Bayer as well. Under the new reign of CEO Bill Anderson, digital health seems to have finally found its positioning in the Consumer Health division. There, the Company is to cooperate with exciting start-ups that collect and analyze consumer data. When it comes to networking and interpreting data using AI, one company in particular stands out at the moment. Palantir is moving out to "dominate the entire market." How? Find out in the comments below.


    Commented by Fabian Lorenz on June 1st, 2023 | 08:45 CEST

    JinkoSolar, BioNTech and First Phosphate with important updates: This is what moves the shares

    • Mining
    • phosphate
    • photovoltaics
    • Biotechnology

    The energy transition is moving forward. In Germany, the traffic light government seems to have agreed on a new heating law. In the US, the agreement between Democrats and Republicans on the debt ceiling is a good sign for the industry because the promotion of environmentally friendly technologies depends on it. JinkoSolar and First Phosphate, among others, should benefit from this. Both companies have published important updates. There is also important news at BioNTech. However, these are not so positive. When will there be new impulses for the share?